Explor Neurosci EN Exploration of Neuroscience 2834-5347 Open Exploration Publishing 10.37349/en.2025.100683 100683 Perspective Moving forward: may some of “functional” gut disorders be reclassified as enteric neuro-gliopathies? https://orcid.org/0000-0002-0237-1812 Bassotti Gabrio Conceptualization Investigation Writing—original draft Writing—review & editing * Gronewold Janine Academic Editor University Hospital Essen, Germany Gastroenterology, Hepatology & Digestive Endoscopy Section, Department of Medicine & Surgery, University of Perugia, 06156 Perugia, Italy *Correspondence: Gabrio Bassotti, Gastroenterology, Hepatology & Digestive Endoscopy Section, Department of Medicine & Surgery, University of Perugia, 06156 Perugia, Italy. gabassot@gmail.com 2025 11 04 2025 4 100683 01 02 2025 21 03 2025 © The Author(s) 2025. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

“Functional” gut disorders are clinical conditions frequently encountered in clinical practice, often characterized by abnormalities of the intestinal sensory and motor functions. Although traditionally believed not harboring organic abnormalities, some of these disorders have been demonstrated to have more or less subtle involvement of the enteric nervous system. This involvement has been especially documented for enteric glial cells, even though other elements may be involved. Given the pivotal role of enteric glial cells in gut pathophysiology and their evident abnormalities in some disorders of gut-brain interaction, it may be time to reconsider their role and recognize them as an important pathophysiological factor in these conditions. Thus, due to the prominent neuronal and glial involvement in some clinically severe forms, it is proposed that at least some of the “functional” gut disorders should be reclassified as enteric neuro-gliopathies.

 Enteric gliopathies enteric neuropathies functional gut disorders Introduction

“Functional” gastrointestinal disorders are clinicopathological conditions frequently encountered in clinical practice, often characterized by sensory/motor intestinal disturbances [1]. These conditions are associated with poor quality of life and high healthcare costs [2, 3]. Of interest, there has been recent literature re-assertion that the diagnosis of these disorders should be based on “excluding organic etiologies of the patient's symptoms” [1]. This statement maintains the old distinction between “functional” and “organic” disorders of the gastrointestinal tract, proposed many years ago [4]. This distinction, however, disregards the accumulating evidence of an organic basis for at least some of these clinicopathological conditions. Indeed, in the last years, it has progressively emerged that some “functional” gut disorders, presently re-named “disorders of gut-brain interaction (DGBI)” [5], may in fact have an organic background when appropriately investigated. Thus, at least for some of them a more appropriate label, such as “entero-gliopathies” has been proposed [6]. In this article, the perspective supporting this claim will be analyzed under the light of these evidences.

 Why moving toward the enteric neuro-gliopathies Inappropriateness of the “functional” definition

By widely accepted definition the term “functional”, when applied to a disease, implies the absence of underlying organic pathophysiological mechanisms or conditions, whether anatomic, inflammatory, neoplastic or otherwise. Thus, the DGBIs (formerly “functional gut disorders”) are usually classified according to the Rome IV criteria [7] and require the exclusion of an underlying or associated organic condition to be diagnosed [1, 7]. However, since the original appearance of Rome criteria in the 80’s, the knowledge about these disorders has considerably increased and the firm belief that no organic abnormality is present has been shaken by solid evidences. In fact, at least some (or some subtypes of) DGBIs may actually display some underlying subtle organic pathophysiological mechanisms as responsible for their clinical manifestations [8, 9]. These abnormalities chiefly involve the cell populations constituting the enteric nervous system (ENS) and/or the mucosal immune system [10, 11], and are usually detected with specific pathologic techniques [12], thereby explaining why in past the routinary assessment by hematoxylin-eosin stains has failed to show them.

 Importance of the ENS in the genesis of gut disturbances

The ENS, also known as “the brain of the gut”, regulates the main intestinal functions (motility, secretion, perception) by means of a complex neural network arranged in several interconnected plexuses. Two of these plexuses are ganglionated and are represented by the submucosal (Meissner’s) and the myenteric (Auerbach’s) plexus, whose cellular components are constituted by a dense array of enteric neurons (EN) and enteric glial cells (EGC) [13]. These latter cells have received in recent years enormous attention by researchers and, due to their multiple functions, are presently considered as a crossway of paramount importance for the homeostasis of the gut [14] (Figure 1). Together with the interstitial cells of Cajal (ICC) [15], responsible for pacemaker activity, EN and EGC govern (by means of their bidirectional communications involving their multiple functions) the complex motor activity of the gut [13]. Thus, as we will see below, it is not surprising that abnormalities involving one or both cell populations may have important pathophysiological consequences, especially concerning intestinal motility [12].

The multiple functions of the enteric glial cells. EGC: enteric glial cells; EN: enteric neurons; ICC: interstitial cells of Cajal

 Clinical entities with documented neuronal and glial abnormalities

In recent years, the attention of researchers has focused on abnormalities involving the cell subpopulations that constitute the ENS. The main findings will be summarized below.

Irritable bowel syndrome

This has traditionally been considered as the prototype “functional” gut disorder, and it represents without doubts one of the most frequently encountered DGBI in the daily clinical practice. Irritable bowel syndrome (IBS) is clinically defined by abdominal pain/discomfort associated with variations of bowel habits (constipation/diarrhea) [7]. Although the diagnosis of IBS is still one of exclusion, some authors, a few years ago, have convincingly demonstrated that in patients with severe IBS may be actually present a low-grade inflammation involving the intestinal ENS [16]. Since then, evidence has mounted confirming that this entity may actually recognize more or less subtle and different abnormalities of the ENS as responsible for at least some of the symptoms [17], especially those related to abnormal gut motility/perception and to the regulation of epithelial barrier functions [18]. Even though most of the evidence had been obtained from animal studies, human investigations have also shown altered interactions between EGC and mast cells and abnormal glioplasticity in these patients [19].

 Chronic constipation

One of the most frequent DGBIs in the clinical practice, chronic constipation (CC) is an umbrella term including several clinical subtypes, ranging from mild symptoms to very severe forms presenting an important decrease (up to the total absence) of colonic propulsive activity [20]. These patients are frequently unresponsive to most therapeutic options [21], and may require surgery to alleviate symptoms. There is presently good evidence, obtained in surgically treated patients with severe and medically refractory CC, that assessment of the ENS may reveal several abnormalities. For instance, most patients with severe slow-transit constipation undergoing colectomy for medically refractory constipation have a significant decrease of EN, EGC, and ICC in the colon, compared to controls [22]. Of interest, these abnormalities are also present in the small bowel [23], providing a possible explanation to the gut dysmotilities frequently reported in these subjects [24]. It is worth noting that a significant decrease of EGC has been also documented in patients undergoing surgery for intractable constipation due to obstructed defecation [25]. Of note, in these patients the EGC and glial filaments were close to degranulated mast cells, suggesting a possible common pathophysiologic event [26].

A significant decrease of colonic EGC has been also reported in surgical samples obtained from constipated patients with Chagasic and idiopathic megacolon undergoing colectomy for severe symptoms [27].

All in all, the above observations suggest that several conditions clinically characterized by the presence of constipation are linked to abnormalities of colonic EGC.

 Chronic intestinal pseudo-obstruction

An infrequent but potentially lethal condition, chronic intestinal pseudo-obstruction (CIPO) is a clinical syndrome characterized by signs and symptoms of intestinal obstruction in the absence of mechanical obstruction [28]. Although several cases of CIPO may be secondary to other pathological conditions (e.g., scleroderma), many patients are classified as “functional gut disorders”. This is due to the fact that usually there are no apparently detectable macro- or microscopic abnormalities in the tissues examined after surgical procedures are carried out in these patients. However, in recent years the diagnostic approach to CIPO has benefitted from more in-depth pathological analyses. For instance, some studies showed an abnormal activity of the EGC as possibly responsible for the intestinal motor abnormalities documented in these patients [17]. Interestingly, a study reported that the localization of some viruses in the EGC of patients with CIPO might suggest a possible pathophysiological role of pathogens in the origin of symptoms in these patients [29]. Other studies showed abnormal glial signaling in these patients, and suggested a possible role for EGC in the genesis of intestinal dysmotilities in subjects with CIPO [30]. The above observations are of paramount importance to address potential new issues for treating these complex conditions [31], often unresponsive even to multiple therapeutic approaches.

 Future directions

The field of neurogastroenterology is ebullient, with new discoveries and new concepts being continuously proposed to the research and the clinical communities. Indeed, the technological advancements to investigate the multi-faceted aspects of the ENS are quite common and rapid. In fact, new methodologies are continuously being proposed and used, such as those developed to profile the enteric trascriptome and cell lineages in animal and human models [32, 33], which could aid future clinical management. Thus, a more precise classification of some DGBIs may contribute to paradigm shifts and breakthroughs in future research.

 Conclusions

At present, there is accumulating evidence that at least some of the previously defined “functional” gut disorders (recently renamed DGBI) may in fact not be “functional” at all. In fact, when properly investigated tissues from some subcategories of these patients may reveal the presence of more or less subtle organic abnormalities. These abnormalities have been mainly described in the ENS of the small bowel and (especially) the colon even though, from time to time, may be also present in the esophagus [34]. However, since these findings have been usually reported in patients with severe clinical involvement requiring a surgical approach to alleviate the symptoms, it is obvious that the results should not be automatically translated to all subjects belonging to these categories (in particular, to IBS and constipated patients).

Although the described anomalies encompass with more or less intensity all the main cell populations of the ENS (i.e., neurons, ICC, and EGC) there are instances in which the constant abnormality only relates to EGC. In particular, it is worth noting the fact that EGC are abnormally reduced in different measure in all patients so far investigated for different subtypes of CC, suggesting a likely pathophysiological role for this cell population. For this reason, it is suggested that the term “neuro-gliopathies” should be added to the classification of at least some subtypes of DGBIs. Of course, further solid evidence is needed to firmly establish this definition, but the time is ripe to move forward and think outside the old schemes.

 Abbreviations CC

chronic constipation

 CIPO

chronic intestinal pseudo-obstruction

 DGBI

disorders of gut-brain interaction

 EGC

enteric glial cells

 EN

enteric neurons

 ENS

enteric nervous system

 IBS

irritable bowel syndrome

 ICC

interstitial cells of Cajal

 Declarations Author contributions

GB: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. The author read and approved the submitted version.

 Conflicts of interest

Gabrio Bassotti who is the Guest Editor of Exploration of Neuroscience had no involvement in the decision-making or the review process of this manuscript.

 Ethical approval

Not applicable.

 Consent to participate

Not applicable.

 Consent to publication

Not applicable.

 Availability of data and materials

Not applicable.

 Funding

Not applicable.

 Copyright

© The Author(s) 2025.

 Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

 Tome J Kamboj AK Loftus CG Approach to Disorders of Gut-Brain Interaction Mayo Clin Proc 2023 98 458 67 10.1016/j.mayocp.2022.11.001 36868754 Neri L Basilisco G Corazziari E Stanghellini V Bassotti G Bellini M et al. LIRS Study Group Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation United European Gastroenterol J 2014 2 138 47 10.1177/2050640614528175 24953097 PMC4040810 Neri L Iovino P Laxative Inadequate Relief Survey (LIRS) Group Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation Neurogastroenterol Motil 2016 28 581 91 10.1111/nmo.12758 26867677 Thompson WG Longstreth GF Drossman DA Heaton KW Irvine EJ Müller-Lissner SA Functional bowel disorders and functional abdominal pain Gut 1999 45 II43 7 10.1136/gut.45.2008.ii43 10457044 PMC1766683 Schmulson MJ Drossman DA What Is New in Rome IV J Neurogastroenterol Motil 2017 23 151 63 10.5056/jnm16214 28274109 PMC5383110 Bassotti G Villanacci V Fisogni S Rossi E Baronio P Clerici C et al. Enteric glial cells and their role in gastrointestinal motor abnormalities: introducing the neuro-gliopathies World J Gastroenterol 2007 13 4035 41 10.3748/wjg.v13.i30.4035 17696219 PMC4205302 Drossman DA Hasler WL Rome IV—Functional GI Disorders: Disorders of Gut-Brain Interaction Gastroenterology 2016 150 1257 61 10.1053/j.gastro.2016.03.035 27147121 El-Salhy M Gundersen D Gilja OH Hatlebakk JG Hausken T Is irritable bowel syndrome an organic disorder? World J Gastroenterol 2014 20 384 400 10.3748/wjg.v20.i2.384 24574708 PMC3923014 Wouters MM Vicario M Santos J The role of mast cells in functional GI disorders Gut 2016 65 155 68 10.1136/gutjnl-2015-309151 26194403 Yuan Y Wang X Huang S Wang H Shen G Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships Gut Microbes 2023 15 2263209 10.1080/19490976.2023.2263209 37786296 PMC10549202 Santhosh S Zanoletti L Stamp LA Hao MM Matteoli G From diversity to disease: unravelling the role of enteric glial cells Front Immunol 2024 15 1408744 10.3389/fimmu.2024.1408744 38957473 PMC11217337 Bernardini N Ippolito C Segnani C Mattii L Bassotti G Villanacci V et al. Histopathology in gastrointestinal neuromuscular diseases: methodological and ontological issues Adv Anat Pathol 2013 20 17 31 10.1097/PAP.0b013e31827b65c0 23232568 Thomasi B Gulbransen B Mini-review: Intercellular communication between enteric glia and neurons Neurosci Lett 2023 806 137263 10.1016/j.neulet.2023.137263 37085112 PMC10150911 Bassotti G Villanacci V Antonelli E Morelli A Salerni B Enteric glial cells: new players in gastrointestinal motility? Lab Invest 2007 87 628 32 10.1038/labinvest.3700564 17483847 Sanders KM Santana LF Baker SA Interstitial cells of Cajal – pacemakers of the gastrointestinal tract J Physiol 2025 [Epub ahead of print] 10.1113/JP284745 37997170 Törnblom H Lindberg G Nyberg B Veress B Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome Gastroenterology 2002 123 1972 9 10.1053/gast.2002.37059 12454854 Linan-Rico A Ochoa-Cortes F Schneider R Christofi FL Mini-review: Enteric glial cell reactions to inflammation and potential therapeutic implications for GI diseases, motility disorders, and abdominal pain Neurosci Lett 2023 812 137395 10.1016/j.neulet.2023.137395 37451357 PMC10952371 Pastras P Aggeletopoulou I Triantos C Impact of Enteric Nervous Cells on Irritable Bowel Syndrome: Potential Treatment Options Microorganisms 2024 12 2036 10.3390/microorganisms12102036 39458345 PMC11510338 Lilli NL Quénéhervé L Haddara S Brochard C Aubert P Rolli-Derkinderen M et al. Glioplasticity in irritable bowel syndrome Neurogastroenterol Motil 2018 30 e13232 10.1111/nmo.13232 29027719 Bassotti G Chistolini F Nzepa FS Morelli A Colonic propulsive impairment in intractable slow-transit constipation Arch Surg 2003 138 1302 4 10.1001/archsurg.138.12.1302 14662528 Bassotti G Satta PU Bellini M Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options Clin Exp Gastroenterol 2021 14 413 28 10.2147/CEG.S256364 34712055 PMC8547593 Bassotti G Villanacci V Maurer CA Fisogni S Fabio FD Cadei M et al. The role of glial cells and apoptosis of enteric neurones in the neuropathology of intractable slow transit constipation Gut 2006 55 41 6 10.1136/gut.2005.073197 16041063 PMC1856399 Bassotti G Villanacci V Cathomas G Maurer CA Fisogni S Cadei M et al. Enteric neuropathology of the terminal ileum in patients with intractable slow-transit constipation Hum Pathol 2006 37 1252 8 10.1016/j.humpath.2006.04.027 16949932 Bassotti G Stanghellini V Chiarioni G Germani U Giorgio RD Vantini I et al. Upper gastrointestinal motor activity in patients with slow-transit constipation. Further evidence for an enteric neuropathy Dig Dis Sci 1996 41 1999 2005 10.1007/BF02093603 8888714 Bassotti G Villanacci V Nascimbeni R Asteria CR Fisogni S Nesi G et al. Colonic neuropathological aspects in patients with intractable constipation due to obstructed defecation Mod Pathol 2007 20 367 74 10.1038/modpathol.3800748 17277762 Bassotti G Villanacci V Nascimbeni R Cadei M Manenti S Antonelli E et al. Increase of colonic mast cells in obstructed defecation and their relationship with enteric glia Dig Dis Sci 2012 57 65 71 10.1007/s10620-011-1848-y 21814802 Iantorno G Bassotti G Kogan Z Lumi CM Cabanne AM Fisogni S et al. The enteric nervous system in chagasic and idiopathic megacolon Am J Surg Pathol 2007 31 460 8 10.1097/01.pas.0000213371.79300.a8 17325489 Giorgio RD Stanghellini V Barbara G Corinaldesi R Ponti FD Tonini M et al. Primary enteric neuropathies underlying gastrointestinal motor dysfunction Scand J Gastroenterol 2000 35 114 22 10.1080/003655200750024263 10720107 Selgrad M Giorgio RD Fini L Cogliandro RF Williams S Stanghellini V et al. JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction Gut 2009 58 25 32 10.1136/gut.2008.152512 18593810 PMC2865195 Ahmadzai MM McClain JL Dharshika C Seguella L Giancola F Giorgio RD et al. LPAR1 regulates enteric nervous system function through glial signaling and contributes to chronic intestinal pseudo-obstruction J Clin Invest 2022 132 e149464 10.1172/JCI149464 35166239 PMC8843750 Burns AJ Goldstein AM Newgreen DF Stamp L Schäfer K Metzger M et al. White paper on guidelines concerning enteric nervous system stem cell therapy for enteric neuropathies Dev Biol 2016 417 229 51 10.1016/j.ydbio.2016.04.001 27059883 PMC5026875 Drokhlyansky E Smillie CS Van Wittenberghe N Ericsson M Griffin GK Eraslan G et al. The Human and Mouse Enteric Nervous System at Single-Cell Resolution Cell 2020 182 1606 22.e23 10.1016/j.cell.2020.08.003 32888429 PMC8358727 Obata Y Castaño Á Fallesen TL Bon-Frauches AC Boeing S Huseynova A et al. Molecular profiling of enteric nervous system cell lineages Nat Protoc 2022 17 1789 817 10.1038/s41596-022-00697-4 35676375 Villanacci V Annese V Cuttitta A Fisogni S Scaramuzzi G Santo ED et al. An immunohistochemical study of the myenteric plexus in idiopathic achalasia J Clin Gastroenterol 2010 44 407 10 10.1097/MCG.0b013e3181bc9ebf 19834336